Toxicokinetics of tabun enantiomers in anaesthetized swine after intravenous tabun administration
In the present study, we report the first in vivo toxicokinetic study of tabun (O-ethyl-N,N-dimethylphosphoramidocyanidate). The toxicokinetics of the enantiomers of tabun were investigated in anesthetized swine after intravenous administration of 3 × LD 50 (161.4 μg/kg) tabun. Blood samples were ta...
Saved in:
Published in | Toxicology letters Vol. 198; no. 2; pp. 177 - 181 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Shannon
Elsevier Ireland Ltd
05.10.2010
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In the present study, we report the first
in vivo toxicokinetic study of tabun (O-ethyl-N,N-dimethylphosphoramidocyanidate). The toxicokinetics of the enantiomers of tabun were investigated in anesthetized swine after intravenous administration of 3
×
LD
50 (161.4
μg/kg) tabun. Blood samples were taken for gas chromatographic–mass spectrometric determination of the tabun enantiomers and for measurement of the activity of red blood cell acetylcholinesterase (AChE) and plasma butyrylcholinesterase (BChE). The tabun enantiomers could be quantified in swine blood to a minimum concentration of 3.0
pg/ml (18.5
pM) and could be detected to a minimum concentration of 1.0
pg/ml (6.2
pM). The concentration–time profiles of both tabun enantiomers were best described by a bi-exponential equation. The elimination of (+)-tabun and (−)-tabun were comparable in the initial phase. In the terminal phase a remarkable difference was found, with terminal half lives of 11.5
min for (+)-tabun and 23.1
min for (−)-tabun. (+)-Tabun showed a markedly longer persistence
in vivo than (+)-enantiomers of other G-type nerve agents and could be detected in all swine at least up to 30
min post-injection, (−)-tabun at least up to 90
min post-injection. These results demonstrate a rather rapid elimination of tabun enantiomers
in vivo and may provide a toxicokinetic basis for the further development and optimization of medical countermeasures against this nerve agent. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0378-4274 1879-3169 |
DOI: | 10.1016/j.toxlet.2010.06.012 |